JP2010509234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509234A5 JP2010509234A5 JP2009535486A JP2009535486A JP2010509234A5 JP 2010509234 A5 JP2010509234 A5 JP 2010509234A5 JP 2009535486 A JP2009535486 A JP 2009535486A JP 2009535486 A JP2009535486 A JP 2009535486A JP 2010509234 A5 JP2010509234 A5 JP 2010509234A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- antibody
- patient
- interleukin
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 31
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 31
- 230000003211 malignant effect Effects 0.000 claims description 12
- 239000012636 effector Substances 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 64
- 230000027455 binding Effects 0.000 description 15
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 13
- 206010066476 Haematological malignancy Diseases 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 102000000013 Chemokine CCL3 Human genes 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 8
- 108090000174 Interleukin-10 Proteins 0.000 description 8
- 102000013462 Interleukin-12 Human genes 0.000 description 8
- 108010065805 Interleukin-12 Proteins 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 8
- 108090001007 Interleukin-8 Proteins 0.000 description 8
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 8
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 8
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 8
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 229940117681 interleukin-12 Drugs 0.000 description 8
- 229940100601 interleukin-6 Drugs 0.000 description 8
- 229940096397 interleukin-8 Drugs 0.000 description 8
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 108700012434 CCL3 Proteins 0.000 description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 description 4
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229960003130 interferon gamma Drugs 0.000 description 4
- 229940076144 interleukin-10 Drugs 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000007541 Preleukemia Diseases 0.000 description 2
- 208000009527 Refractory anemia Diseases 0.000 description 2
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85653006P | 2006-11-02 | 2006-11-02 | |
| US87443906P | 2006-12-11 | 2006-12-11 | |
| US94302107P | 2007-06-08 | 2007-06-08 | |
| PCT/US2007/083508 WO2008058021A2 (en) | 2006-11-02 | 2007-11-02 | Methods of treating neoplastic, autoimmune and inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509234A JP2010509234A (ja) | 2010-03-25 |
| JP2010509234A5 true JP2010509234A5 (enExample) | 2010-12-16 |
Family
ID=39365271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535486A Pending JP2010509234A (ja) | 2006-11-02 | 2007-11-02 | 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20110038856A1 (enExample) |
| EP (1) | EP2084527A4 (enExample) |
| JP (1) | JP2010509234A (enExample) |
| AU (1) | AU2007317333A1 (enExample) |
| CA (1) | CA2667808A1 (enExample) |
| WO (1) | WO2008058021A2 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2163256B1 (en) | 2001-05-11 | 2015-09-02 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| WO2008058021A2 (en) | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| MX338185B (es) | 2007-01-25 | 2016-04-05 | Dana Farber Cancer Inst Inc | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. |
| EP2134854B1 (en) | 2007-03-15 | 2015-04-15 | Ludwig Institute for Cancer Research Ltd. | Treatment method using egfr antibodies and src inhibitors and related formulations |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| SI3187506T1 (sl) | 2007-05-21 | 2019-08-30 | Alderbio Holdings Llc | Protitelesa proti IL-6 in njihova uporaba |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| WO2009023265A1 (en) | 2007-08-14 | 2009-02-19 | Ludwig Institute For Cancer Research | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
| EP2300022A2 (en) | 2008-04-25 | 2011-03-30 | Duke University | Regulatory b cells and their uses |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| WO2011022861A1 (zh) * | 2009-08-31 | 2011-03-03 | 西安力邦医药科技有限责任公司 | 氟维司群纳米球/微球及其制备方法和用途 |
| AU2010293383B2 (en) | 2009-09-10 | 2014-12-18 | Kyowa Kirin Co., Ltd. | Medicament including antibody composition specifically bound to human CC chemokine receptor 4 (CCR4) |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| EP2504030A4 (en) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP |
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| US10131875B2 (en) | 2010-08-04 | 2018-11-20 | Duke University | Regulatory B cells and their uses |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| GB201016864D0 (en) | 2010-10-06 | 2010-11-17 | Univ Aston | Therapeutic methods |
| EP2643018B1 (en) | 2010-11-23 | 2020-10-14 | AlderBio Holdings LLC | Anti-il-6 antibodies for the treatment of oral mucositis |
| WO2012088272A1 (en) * | 2010-12-21 | 2012-06-28 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
| CA2883711A1 (en) | 2012-09-07 | 2014-03-13 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
| CA2886474A1 (en) | 2012-09-28 | 2014-04-03 | Ellis KLINE | Glycosidase regimen for treatment of infectious disease |
| KR20150107738A (ko) * | 2013-01-18 | 2015-09-23 | 엘리스 클라인 | 암의 면역 프로그래밍 및 치료를 위한 선택적 글라이코시다제 섭생 |
| WO2014159923A1 (en) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Enhancement of vaccines |
| AR097648A1 (es) * | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
| GB201319620D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
| WO2015085171A1 (en) * | 2013-12-06 | 2015-06-11 | Adventist Health Systems/Sunbelt, Inc. | Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| JP2018516248A (ja) | 2015-05-29 | 2018-06-21 | アンフィヴェナ セラピューティクス，インク． | 二重特異性のｃｄ３３およびｃｄ３結合タンパク質を使用する方法 |
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| KR20180033502A (ko) | 2015-06-12 | 2018-04-03 | 알렉터 엘엘씨 | 항-cd33 항체 및 그의 사용 방법 |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| EP3442584B1 (en) | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| JOP20170091B1 (ar) * | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
| US11110179B2 (en) | 2016-06-03 | 2021-09-07 | Seagen Inc. | Combination of CD33 antibody drug conjugates with chemotherapeutic agents |
| EP3469001A4 (en) | 2016-06-09 | 2020-05-06 | Seattle Genetics, Inc. | COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS |
| EP3554515A4 (en) | 2016-12-15 | 2020-08-26 | Duke University | B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS |
| CA3057447A1 (en) | 2017-08-03 | 2019-02-07 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| US20230132400A9 (en) * | 2017-11-10 | 2023-04-27 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| BR112021003016A2 (pt) | 2018-08-31 | 2021-05-18 | Alector Llc | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um anticorpo e para prevenir, reduzir o risco ou tratar uma doença e composição farmacêutica |
| US20210324076A1 (en) * | 2018-10-12 | 2021-10-21 | Amphivena Therapeutics Inc | Cd33×cd3 binding proteins for treating inflammatory conditions and diseases |
| AU2020265679A1 (en) | 2019-04-30 | 2021-12-23 | Senti Biosciences, Inc. | Chimeric receptors and methods of use thereof |
| WO2021059133A1 (en) * | 2019-09-23 | 2021-04-01 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec - Associação | Polymeric micelle, methods of production and uses thereof |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| JP7411875B2 (ja) * | 2020-10-08 | 2024-01-12 | 株式会社 キュロム・バイオサイエンス | ベータ－ラパコンを有効成分として含む胆汁うっ滞性肝疾患予防又は治療用薬学組成物 |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU659083B2 (en) * | 1989-12-14 | 1995-05-11 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof |
| US6599505B1 (en) * | 1992-04-10 | 2003-07-29 | Research Development Foundation | Immunotoxins directed against CD33 related surface antigens |
| US6007814A (en) * | 1992-06-15 | 1999-12-28 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof |
| EP0958304A4 (en) * | 1996-08-09 | 2002-01-16 | Human Genome Sciences Inc | NUCLEOTIDE SEQUENCE ENCODING PROTEIN TYPE CD33 |
| US6653104B2 (en) * | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US7194554B1 (en) * | 1998-12-08 | 2007-03-20 | Nomadix, Inc. | Systems and methods for providing dynamic network authorization authentication and accounting |
| US6759045B2 (en) * | 2000-08-08 | 2004-07-06 | Immunomedics, Inc. | Immunotherapy for chronic myelocytic leukemia |
| WO2004043461A1 (en) * | 2002-11-06 | 2004-05-27 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| HUE026914T2 (en) * | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| US20060204502A1 (en) * | 2004-11-22 | 2006-09-14 | Borea Pier A | Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists |
| JP2008523083A (ja) * | 2004-12-08 | 2008-07-03 | イムノメディクス， インコーポレイテッド | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
| WO2008058021A2 (en) | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
-
2007
- 2007-11-02 WO PCT/US2007/083508 patent/WO2008058021A2/en not_active Ceased
- 2007-11-02 EP EP07863851A patent/EP2084527A4/en not_active Withdrawn
- 2007-11-02 AU AU2007317333A patent/AU2007317333A1/en not_active Abandoned
- 2007-11-02 JP JP2009535486A patent/JP2010509234A/ja active Pending
- 2007-11-02 CA CA002667808A patent/CA2667808A1/en not_active Abandoned
- 2007-11-02 US US12/513,313 patent/US20110038856A1/en not_active Abandoned
-
2008
- 2008-04-11 US US12/101,785 patent/US7695716B2/en active Active
-
2010
- 2010-02-26 US US12/714,235 patent/US20100215653A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509234A5 (enExample) | ||
| Berraondo et al. | Cytokines in clinical cancer immunotherapy | |
| Barton et al. | Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model | |
| Spinas et al. | Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. | |
| Moldawer et al. | The role of cytokines in cancer cachexia | |
| Szekanecz et al. | Macrophages and their products in rheumatoid arthritis | |
| Yan et al. | Therapeutic potential of cytokine and chemokine antagonists in cancer therapy | |
| Nemunaitis et al. | Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation | |
| Couriel et al. | Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation | |
| Weisbart et al. | Physiology of granulocyte and macrophage colony-stimulating factors in host defense. | |
| Davies et al. | Clinical experience of IL-6 blockade in rheumatic diseases—implications on IL-6 biology and disease pathogenesis | |
| JP2006514024A5 (enExample) | ||
| Kremer et al. | lnterleukin-1-6 and tumor necrosis Factor-α release is down-regulated in whole blood from septic patients | |
| Lentsch et al. | Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2 | |
| Engles et al. | Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia–reperfusion injury | |
| Welborn 3rd et al. | A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. | |
| Tsimberidou et al. | TNF-α targeted therapeutic approaches in patients with hematologic malignancies | |
| Higuchi et al. | Inhibition of ligand binding and antiproliferative effects of tumor necrosis factor and lymphotoxin by soluble forms of recombinant P60 and P80 receptors | |
| Koumakis et al. | Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide | |
| Franks et al. | Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival | |
| Xing et al. | Consideration of cytokines as therapeutics agents or targets | |
| Brok et al. | IFN-γ-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells | |
| Perez et al. | Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study | |
| Steinhauser et al. | New frontiers in cytokine involvement during experimental sepsis | |
| Van Montfrans et al. | Immunotherapy of Crohn′ s disease |